1. ABVD remains the standard first-line treatment for Hodgkin's lymphoma as it obtains similar survival results to other regimens but is less toxic. 2. For aggressive NHL, an interim positive PET scan after 2 cycles of chemotherapy is not necessarily predictive of treatment efficacy and should not be used to guide treatment. 3. In follicular lymphoma, watch-and-wait is an option for early stage disease but single agent rituximab may allow more patients to avoid chemotherapy compared to watch-and-wait.